ArticleLeukemia2023

CD7 targeted "off-the-shelf" CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies.

Shiqi Li et al.PubMed ↗Publisher ↗

No numbers read from the abstract.